Vertu Medical Technologies

Whitepaper Version 1.0

PERFORMANCE POSITIVITY PARADIGM PASSION

VISION VALUE VALOR VIRTUE



INNOVATION INVENTION INVESTMENT

PERSEVERANCE PROSPERITY PHILANTHROPY PROACTIVE

Vertu Medical Technologies

The Healthcare Rapid Innovation Networking, Intellectual Property, Blockchain Tracking, Product Developing, and Medical Technology Investing Conglomerate.

Whitepaper Version 1.0

Last update: October 12, 2022

Table of Contents

Legal Disclaimer

The information in this document is subject to change or update without notice and should not be construed as a commitment by Vertu Medical Technologies (VMT) or Vertu Foundation. This document and parts thereof must not be reproduced or copied without VMT's written permission, and the contents thereof must not be imparted to a third party nor be used for any unauthorized purposes.

Forward Looking Statements Disclaimer

Vertu Medical Technologies, LLC. is known as the "Company" within this disclaimer. Certain information set forth in this document contains "forward-looking information", including "future oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Eligibility

All cryptocurrency token purchases, or investments are subject to rules and regulations applicable in the buyer's country. Vertu Medical Technologies, LLC. cannot be held liable for investments or token purchases by ineligible parties. Invest at your own risk.

Mission

Dr. Morris defines the company mission as jointly interacting in program and project ventures to perpetually introduce new and improved innovations that facilitate patient care. Through integration and introduction of novel technologies and medical device innovations into the current healthcare arena Vertu Medical Technologies will provide proprietary solutions. Our goal is to continually expand our Vertu Innovation Platform of collaborative knowledge and virtuous efforts with an unwavering dedication to provide significantly facilitated and enhanced health care of the future to all individuals.

Executive Summary

Introduction

Vertu Medical Technologies (Vertu Medical) is a holding company with three core divisions:

- The Vertu Healthcare Technology Development Network or Vertu Innovation Platform (VIP)

- The Collaborative Endeavor Opportunities (CEO) Division that produces, markets products and oversees businesses generated from VIP, and

- The Aegis Medical Technology Fund that can support C.E.O. projects and outside businesses with venture capital eventually providing a return to investors.

Technology Solutions

The founder of Vertu Medical, Dr. Dennis Morris, has transferred an initial 10 patent pending healthcare innovations to Vertu Medical under the CEO Division to enhance the value of the company. These initial patent pending projects alone potentially represent hundreds of millions of dollars of future revenue in the form of royalty payment income for Vertu Medical and distributions to investors.

In order to link the participating healthcare providers into an innovation development network under the Vertu umbrella, Vertu Medical will develop a private node, customized version of the EOSIO blockchain employing the Goods Non-Fungible Token (NFT) standard. This tailored blockchain will enable an innovation tracking, development, distribution and royalty payment system based on NFTs linked to the collaborative network of healthcare providers contributing to the innovation. Eventually this blockchain could supplant the need for the lengthy and delayed patent process through conventional national patent agencies and form a global international intellectual property (IP) registry.

Process Solution

The Vertu Innovation Platform, CEO division, and Aegis fund will use a bottom up, front line approach to innovation, R&D fund distribution, and royalty sharing. Instead of localized and unsupported innovation efforts randomly arising both within and outside of the healthcare system, Vertu Medical will provide a framework for incentivizing and shepherding innovations from concept to prototype through testing to final market introduction using the Vertu EOS NFT token tracking platform.

Market Approach

Vertu Medical will initially seek out licensing arrangements for the existing patent pending innovations and all future innovations emanating from the Vertu Innovation Network, the Aegis Fund investments and the CEO platform. Licensing the market

ready innovations, rather than manufacturing directly, allows Vertu Medical to avoid costly investments in plant and equipment while getting to market faster with a focus on R&D instead of operations. This model imitates legendary innovators including Apple, Nike, and Deka Research and Development Corp.

Values

Vertu Medical focuses on developing healthcare solutions to improve lives, reduce medical treatment costs, and financially reward those contributing to these innovations.

The Problem

1. Innovation processes are top down instead of bottom up from healthcare providers and institutions.

2. Frontline healthcare providers are not incentivized to create technical innovations with profit sharing or royalties and are financially constrained without access to corporate R & D budgets.

3. Medical technology development cycles are too long and result in too few impactful devices, treatments, or processes.

4. Medical intellectual property (IP) is owned by a select group of corporations instead of shared by a large group of direct healthcare providers.

5. Regarding the United States; as one example, the current IP development, processing, and approval process is backlogged by over 750,000 U.S. patents pending and needs a federated, blockchain approach to resolve it.

6. Medical technology development investments are largely controlled by a small group of publicly traded companies rather than by the frontline healthcare providers who are better positioned to create the medical advances.

7. Global IP filing is prohibitively expensive and requires separate filings for each major country.

8. Patent infringement cases crossing borders present legal framework challenges and patent law disparities that make global IP protection difficult to achieve or enforce.

Intellectual Property Development Inventor's Options

INVENTOR SELF FUNDS INVENTION

- Inventor commonly told idea is a winner and encouraged to develop it
- Inventor subconsciously avoids competition or pre-existing product investigation
- Full exposure to IP theft at every step
- Inexperienced in the process
- Paralysis by over analysis
- Prohibitively expensive
- Time consuming
- Patent process prolonged
- FDA application expensive and prolonged
- Manufacturing responsibilities
- Marketing responsibilities
- Sales responsibilities
- Quality assurance duties
- Product liability exposure

RECRUIT PRODUCT DEVELOPMENT COMPANY

- Submission portal confiscates project in fine print
- NDA agreements from the company are not binding
- Projects must conform to current company projects to be considered
- Most submissions denied automatically yet still investigated by company
- Company steals idea and claims it was already in its product pipeline
- Company meets and secretly records discussions about other ideas of inventors
- Company clauses allow development of project by company after one to two years without inventor stake
- Insider IP theft and intentional delay until sister company patents idea first
- Successful ventures receive low ownership royalties

ENTER VERTU MEDICAL'S PRODUCT DEVELOPMENT

- Concept submissions immediately time stamped, documented with biometric identification with encryption key only known to innovator
- inventor is granted immediate provisional patent protection
- Immutable inventor protections built in
- Private member website portal to track entire product development chronology
- Concept background investigation and patent searches provided
- AI and global collaborative input collaboration provided
- Inventor funding provided from concept to final version of device
- All engineering and prototyping provided
- FDA application provided if applicable
- Global product commercialization of invention provided
- Royalty distributions in open ledger accounting
- Latest Web Crypto API
- Multiple storage options
- Legal compliance

Vertu Medical's High-Level Solution

1. Create a global healthcare innovation provider network that share development, R&D, data, testing, and engineering burdens to get to market faster with improved products.

2. Develop a platform for distributing IP royalty payments throughout the development network to incentivize participants to create more effective technology at a faster pace.

3. Develop an IP tracking system from concept to prototyping, testing, engineering, licensing, commercialization, and distributing royalty payments using a private, customized blockchain with a utility token.

4. Distribute the ownership of healthcare IP to the frontline providers that contributed to its development using the IP blockchain.

5. Help resolve the patent process backlog by applying non-fungible, immutable, time stamped and private key serialized tokens that replace the concept of patent filings with blockchain titles to innovations.

6. Initiate the patent network with the initial 10 potentially patentable projects to both fund the development and to help verify the future processing method of healthcare innovations or patents.

7. Create a medical technology investment resource called the Aegis Medical Technology Fund that will help underwrite innovations generated by the Vertu Innovation Platform or externally developed innovations and businesses as determined by fund management.

8. Provide a sole source innovation engineering, marketing, logistics, and management division for transforming ideas into commercially successful products.



Vertu Medical Solution Details

Dr. Morris is seeding an initial 10 medical innovation projects from conceptual to working prototype stages for VMT to generate royalty revenue once VMT develops the innovations to the market launch stage. The initial 10 Innovation Projects are prioritized according to the maturity of development and have been designated the **ALPHA GROUP**.

The **ALPHA GROUP** of Innovation Projects will serve as the Vertu Medical Technologies START-UP mechanism. Proceeds from the commercialization and marketing of these initial 10 innovation projects will serve to provide funding for the forthcoming **BETA GROUP** of projects to be extrapolated from the Company project portfolio. A similar mechanism of the propagation of groups of Innovation Projects; first being adopted into the Vertu Medical Project Pipeline, then categorized with respect to priority, then processed through the Company's

proprietary Product Realization System and finally commercialized, will serve the success of the Company in perpetuity.

START-UP VERTU MEDICAL INNOVATIONS PORTFOLIO ALPHA GROUP:

The Initial 10 Innovation Projects

1. NOVEL SURGICAL INSTRUMENT TECHNOLOGIES
2. CRITICAL CARE OXYGEN SATURATION DETECTION DEVICES
3. AIRWAY MANAGEMENT TECHNOLOGIES
4. PREVENTION OF SUDDEN CARDIAC DEATH IN ATHLETES
5. REVOLUTIONARY SUMMATION EKG TECHNOLOGIES
6. VARIABLE FREQUENCY UV LIGHT STERILIZATION
7. SUMMATION TECHNOLOGIES APPLIED TO PHYSIOLOGIC DATA DETECTION
8. FEMININE HYGIENE TECHNOLOGIES
9. BIOPHASIC SENSORY STIMULATION TECHNOLOGIES
10. INFANT ENVIRONMENT TECHNOLOGIES

Note:

Considering length constraints of whitepaper presentations, Vertu Medical Technologies has chosen the initial one of the **ALPHA GROUP** Healthcare Innovation Projects to further discuss herein. It is our intent for this project elaboration to exemplify, to our investors, the **DISRUPTIVE MAGNITUDE** on the Healthcare Industry that Vertu Medical Technologies' novel and proprietary innovation portfolio offers.

For a detailed and informative description of the entire Alpha Group of our initial ten projects listed above, please refer to our website Project Portfolio Portal. Currently a brief and expanded abstract description is provided for each project.

The Project Portfolio Portal will be a convenient means for investor / innovator members to be completely informed as to the product realization status of all the Vertu Medical Technologies pipeline projects. Items referencing existing and new project details will eventually include; for example: abstract summaries, project participants, project status from conceptualization through prototyping, project patent status, commercialization status and financial remittance for our participants and investor members.

Additional to the following expanded presentation of the first Innovation Project of the ALPHA GROUP; the Surgical Instrument Technologies, a detailed Financial Model is later provided here within. It will be made evident to our investors that this single breakthrough technology project of the Company will provide a significant ROI potential for investors as well as a revolutionary **VALUE** improvement to the surgical instrument industry.

Revolutionary Surgical Instrument Technologies

BRIEF ABSTRACT:

Benefits: Allows ambidextrous surgical instrument use, introduces ambidextrous surgical technique training, and reduces surgical errors. Both right and left-handed surgeons can operate more efficiently. Reduces cost of purchasing multiple sets of surgical instruments.

Technology: Proprietary, patent pending locking mechanism and designs.

Market Impact: Estimate $25 - 250 million per year

Industry Insights:

Proof of market size: Global Surgical Equipment Market was valued at $9,783.8 million in 2016 and is expected to reach $15,737.1 million by 2023 supported by a CAGR of 7.0% during the forecast period 2017 to 2023. Surgical equipment are the medical devices used to cut, coagulate, desiccate, and fulgurate the body tissues during the surgical procedures.

(Source: https://www.alliedmarketresearch.com/surgical-equipment-market)

Development Stage: Engineered, tested, ready for market

Time to Market: 12 - 18 months

EXPANDED ABSTRACT:

Vertu Medical will soon be a disruptor in the surgical instrument arena with the introduction of our revolutionary new surgical instruments design and technologies. Vertu Medical has solved the Gordian Knot impasse of centuries old surgical instrument designs; laden with inherent design flaws, that have proven to have unintentional negative consequences to patients. A primary example of conventional surgical instrument design flaws is that of the locking mechanism. Those instruments that require locking mechanisms are right hand biased to the degree that left-handed medical students are often dissuaded from applying for surgical residency positions. Additionally, even right-hand dominant surgeons are often forced to disengage locked surgical instruments with the left hand when they are performing emergency interventions or being positioned across the surgical table, even in a controlled setting, assuming the role of assistant surgeon. This unorthodox disengagement of the conventional locking mechanisms has proven too often to damage delicate tissues or structures of the patient or animal undergoing a surgical procedure.

Over the past fifty years or so, as technology advanced, many attempts have been made to provide viable solutions to the right-hand biased locking mechanisms which have resulted in alternative configurations that simply have not nor will not ever be adopted in the surgical instrument arena. Often these attempts have mandated additional attachments to the instrument, additional maneuvers required to reverse the locking mechanism components or designs so cumbersome that the instrument itself would probably pose a danger to delicate structures. Simply put, a surgeon is not going to use any new instrument design that significantly looks different from what he or she has been trained with or requires additional maneuvers to achieve the same function. Also, with healthcare cost constraints being as they are, surgical companies would not be able to compete by manufacturing surgical instruments with additional components that would require additional manufacturing equipment and assembly labor. More so, even a single case of a lost component, from those attempted designs requiring them, left inside a patient would legally devastate the company that produced it.

Vertu Medical Technologies took on this century old surgical instrument locking mechanism problem and did what has been said to be impossible. Vertu's novel medical instrument designs coupled with the means and methods provided offer several distinct advantages over current and prior art. One improvement, utilizing the provided design of inventor's surgical and medical instrument releasable locking device; for those instruments requiring such components, provides a permanently attached, rigid, durable locking device that is horizontally oriented thereby permitting an identical left and right handed surgical technique to engage or disengage the locking mechanism of the device.

Our petitioned solution provides an improved ergonomic design and locking section serving to replace the existing instrument handle section and locking sections of those surgical and medical instruments that function with pivotally connected angular lever arms that scissors to open and close a gripping section. The improved horizontally oriented

releasable locking device section provided allows an ambidextrous user means for engaging and disengaging the locking devices with identical surgically trained technique whether user's left or right hand is being utilized. The invention's novel design grants the surgical and medical instrument industry a universally designed instrument and locking device applicable to any and all medical and surgical instruments requiring such a locking component for applicable function, capable of performing traditional and ambidextrous utility.

Our 'Open Loop' patent petitioned designs provide for an absolute ambidextrous right or left hand engaging and disengaging function that is undetectable to a surgeon. Simply put, a surgeon given our instrument designs, being behind a poster board obstructing his or her view, would engage and disengage the locking mechanism with the exact same maneuvers of the right or left hand and sense absolutely no difference from that in current use.

This breakthrough solution that Vertu Medical Technologies now provides will serve to prevent the unintentional harm to delicate structures due to unorthodox opening and closing current available surgical instruments, being right hand biased, with the left hand. Additionally, surgical residents will soon be able to use our technology to train ambidextrously during medical school and residency training and carry the dexterity into private practice. Most importantly, the reduction in harm to delicate structures logically will result in future medical liability from using outdated standard conventional instrument designs. It is our intention to dominate the twenty-billion-dollar yearly surgical instrument market with manufacturing applications.

During the interval past three years our petitioned "Open Loop Technology" reconfiguration has undergone the scrutiny of finite element analysis for material stressors as well as continuous repetitive engagement and disengagement of our revolutionary locking mechanism nonstop without a single failure.

There are many dozens of surgical instruments that require locking mechanisms to serve their function. With Vertu Medical Technologies' novel ambidextrous locking mechanism, stem reconfigurations as well as novel distal portion grasping structure improvements, the Company intends to develop a complete line of proprietary surgical instruments of various function and sizes.

With the breakthrough advantages provided through our novel surgical instrument technologies, we believe our exclusive and proprietary instrument portfolio will initiate a paradigm shift in surgical training ambidexterity. It is also our sincere belief that the VALUE ADD to the Surgical Healthcare Industry will rapidly propel Vertu Medical's surgical instrument division to be the leading global supplier of the finest surgical instruments available.

Insight

The 10 innovations referred to above: VMT's initial base of future healthcare products, present multi-billion-dollar revenue opportunities. When these products achieve greater than 5% market penetration in their respective healthcare niches, the value of VMT and the profit-sharing dividends allocated to token holders will support double digit yearly dividend gains.

The other multi-billion-dollar business proposed by VMT involves a new, unique, and seamless method of incentivizing innovations from initial concept through all the phases and joint ventures leading to introducing the innovation into the marketplace. Combining the wisdom of a global network of healthcare providers into the novel innovation production system will accelerate the pace of innovation while critically increasing their quality and daily impact. Read on to learn about the exciting new Plexus Innovation Network.

1. Vertu Innovation Platform for Healthcare Technology Development

The Vertu Innovation Platform consists of healthcare providers organized with incentives for generating new treatment ideas, a format for recording these ideas, a path for turning ideas into marketable products, a process that handles the technical details of product development, and distinct phases that accurately describe the status of the concept.

Vertu envisions linking healthcare providers into a programmatic development network for healthcare innovations that flow directly into an engineering or research and development process and eventual manufacturing and royalty payments.

A. Vertu Components:

a. A proactive problem to solution framework that incentivizes frontline medical staff to create impactful healthcare innovations.

b. A selection methodology for sifting through potential innovations that could have the highest patient benefit.

c. A research and development sequence that provides interdisciplinary expertise from mechanical, electrical, manufacturing, biochemical, modelling, software development and integration teams to shepherd ideas into consumer ready products.

d. A royalty, manufacturing, distribution, and shared compensation system to reward the innovation developers.

The Vertu Innovation Platform requires a central blockchain for tracking the disparate ideas and projects from around the work in a definitive manner. The Vertu IP Blockchain handles this central task.

B. IP Development Tracking Blockchain: Chain, Tokens, Confirmation, Data Structure, Capabilities

The Vertu Innovation Platform (VIP) will depend on blockchain technology to track innovations from inception to market introduction.

Underlying Chain Technology:

Several potential protocol methods could be used for this intellectual property development tracking system.

EOSIO is the most likely blockchain technology for creating the Vertu IP Development Tracking Blocking because of its adaptability, new dGoods protocol, speed of confirmation, scalability, and easy integration with a multitude of applications.

Tokens:

The tracking tokens will be called VIP and be Non-Fungible Tokens (NFTs) for the purposes of assigning titles to each innovation step.

Confirmations:

The standard EOSIO protocol will be employed for confirmations unless the Vertu IP blockchain develops a need to modify this proven process.

Data Structure:

Each VIP NFT will be linked to those related VIP NFTs that preceded the innovation and future innovations building on the ideas assigned to previous VIP NFT. The temporal line of VIP NFTs will be categorized under the heading of the general innovation with private keys controlled by the relevant innovators.

Capabilities:

The primary objectives of the Vertu intellectual property development tracking system include:

a. **Redefining and supplanting the legacy patent application process including eliminating the conventional, lengthy review processes and multinational submissions by using A.I. comparison engines.**
b. **Eliminating contested patent applications by employing an immutable blockchain innovation date stamp.**
c. **Reducing the expense of creating patent applications by using pre-formatted development frameworks that eventually can be summarized in the form of a generally acceptable worldwide patent application specific to the healthcare industry, but broadly applicable to other industries upon further development.**
d. **Easily tracking all contributors to innovations via confirmations of either engineering input or conceptual development.**
e. **Using the facile method of tracking contributors to then tokenize their contributions and reward them via smart contracts that divide up royalty payments per the development contributors list. This methodology is a relatively straightforward application of blockchain technology but is not being applied within the medical device innovation industry.**

Insight

The last section of VMT's business silos involves funding and allocating resources for developing innovations, monetizing them, rewarding contributors from the Vertu Innovation Platform, enabling final regulatory approval and business start-up with a sufficient capital base. The Aegis Medical Technology fund is designed to maximize returns on capital throughout VMT's business operations and through strategic outside investments. The following section details how the Aegis Medical Technology Fund will address these wide-ranging objectives.



C. Aegis Medical Technology Fund: Fund Objectives, Advantages, Focus, and Process

Fund Objectives:

Developing medical technology that requires government approval as well as insurance verification is typically a prohibitively expensive undertaking.

The cost to develop a new drug is around $2.5 billion with over 90% of phase I candidates never even getting close to the finish line. Even though medical devices are much easier to get through FDA approval, the average “cost” is still several million US dollars to get that regulatory stamp.

Vertu Medical has segmented the funding of the Vertu Innovations Platform, including the intellectual property blockchain enabling VIP, plus potential external medical business opportunities into the Aegis Medical Technology Fund.

The Aegis fund will serve as the financial manager to allocate the royalty payments, the development funds, the operating expenses, capital project funds, and business opportunity venture capital throughout the Vertu Medical group of projects or companies.

Fund Advantages:

- By tracking innovations developing from the Vertu Innovation Platform, the Aegis Fund will get early notice of potential technology, well ahead of any other investment vehicle.

- The fund’s investment guidance board will be comprised of leading medical professionals that can rapidly and accurately assess new technology for investment.

- There will be a constant flow of exceptional investment opportunities flowing from the Vertu Innovation Platform as well as external opportunities, enabling the Aegis fund to select only the most promising projects.

- The Aegis fund will be able to monitor and guide projects through regulatory hurdles and market introduction through close, expert supervision that other investment vehicles generally lack the capacity for.

Fund Focus:

Aegis will focus on accessible healthcare technology that broadens the reach of medical treatments to underserved groups, enhances treatment outcomes, and minimizing patient risks. The business objective is to find projects that can be delivered to the market within and average of 2 - 5 years, including testing, regulatory approval, and manufacturing in commercial quantities.

Allocation Process

Medically trained fund managers including Vertu's founder, will allocate resources based on several criteria:

a. The potential beneficial impact of the medical innovation to end-users, The potential market penetration and competitive position against existing technology,

b. The potential market penetration and competitive position against existing technology,

c. The potential for rapid return on investment when factors a and b are considered primarily, and,

d. Adherence to the core principles of focusing on medical innovations that have broad impact vs innovations with narrow, yet still beneficial impact.

The Aegis fund will employ a hybrid combination of artificial intelligence to determine what the investment priorities should be from a wide selection of medical innovations, as well as business opportunities, and even partnerships balanced with input from the financial operations board consisting of medical professionals with financial acumen.

Insight

The following section details how the Vertu business integrate to form an innovation and healthcare distribution business powerhouse.

2. Vertu Business Silos

A. Vertu Product Development Process

a. Vertu certified medical innovation centers that are part of the Vertu Innovation Platform are allowed to participate and feed the Vertu development process. Gaining certification requires signing agreements to be a member of the Vertu Innovation Platform, adhering to the standards, and installing or using the intellectual property tracking system.

b. Part of the VIP on-boarding sequence involves educating and incentivizing the frontline healthcare professionals to begin generating medical innovations. The incentives can be in the form of employee recognition, cash payments, token distribution or any other method that creates the environment for the medical professionals to devote some of their precious time towards improving medical technology.

c. Each Vertu development node or member of the network whether it is a hospital, or a private practice, or a trauma care center or even a research and development member at a university, will have access to the Vertu medical development blockchain tracking system.

d. From the idea inception for the medical innovation through development of a prototype, or even the engineering process involved in assessing the development of the prototype, all steps in the cycle must be entered by the relevant personnel into the Vertu medical development tracking system. Since each relevant member of the healthcare team will have a private key that deterministically verifies their contribution and access to the development process plus timestamps it and records precisely the contribution in the form of either drawings, descriptors, specifications, video, images or any other form of data, the product development process is secured, confirmed, traceable, and without contribution ambiguity. The only claims that would be valid regarding who contributed to a particular novation are those that can be verified with this blockchain medical innovation tracking system.

e. There will be some mechanism for voting or approving which concepts can be funded for further development. This process could involve token voting within the Vertu development blockchain or could be relegated to a fund allocation board or network. More than likely, the initial funding mechanism will require a board review to determine whether or not funds can be allocated to pay for certain phases of the innovation's development. The point at which funding would normally be required involves creating the prototype. Prior to creating a prototype, most innovations simply are theoretical exercises and funding would not be required.

f. As the medical innovation proceeds from concept through development work into engineering, prototyping, testing and verifying and then eventually even FDA approval, the blockchain has a sequential record of every single activity related to this medical innovation. Once the time comes to apply for a patent there is no doubt who was involved in the project, when and what they contributed to the project, the origin date of the project, and the eventual final development and submittable form of the medical innovation.

g. The Vertu medical innovation development blockchain can then supply the diagrams, the core functionality, the core improvements, and even the claims that would be turned into the patent. This could potentially be done by AI but is more likely to be finalized by patent agents or patent attorneys. After

the Vertu development blockchain demonstrates its utility and superior functionality over the previous way of obtaining patents and applying for them, it may be able to supplant or bypass the current backlogged process of submitting patent applications to the US patent office. The same advantages could be used for worldwide patents.

h. At its highest embodiment, the Vertu medical innovation development blockchain or framework would be able to support patents of all types including medicine patents, medical device patents, and expand to general intellectual property. The system could be presented as software as a service for every company to use on the innovation side of their product development process.

i. All of the sketches and engineering files can be integrated into 3-D CAD CAM systems using the common 3-D modeling formats so that the development work in the early phases of an innovation can be easily imported into standard engineering 3-D CAD systems. The reason for this is that typically medical professionals are not experts at using 3-D CAD CAM systems. However, once the VIP gains a foothold and becomes a routine practice, it's foreseeable that hospitals will have a small staff devoted to transferring ideas from scratch pads into 3-D CAD models and, potentially, even farther along the development process.

j. The end result and goal of each medical innovation is to achieve market introduction by passing the FDA standards, and to become a successful medical device. Upon market introduction, and presumably the profit flowing from the market introduction, the next step for the Vertu development blockchain is to allow the royalties to be distributed to those that contributed to the medical innovation. This could take the form of tokens being distributed via the Vertu development blockchain or it could go through the Aegis fund as described in the Aegis fund section.

Insight

The above section explains the flow of innovations within the Vertu Innovation Platform. Powering new ideas through the Vertu Innovation Platform requires allocating funds among competing products. The Aegis fund, covered in the following section, details this high-value process.

Vertu Medical's Business Dynamics



3. IP Blockchain tracking concept through royalty payments

a. One of the main value adds of the VIP is access to the IP or intellectual property blockchain tracking concept explained in an earlier section. This IP blockchain makes tracking each of the contributors to various innovations relatively trivial based on which wallet or private key accessed the IP blockchain. Identifying the relevant contributors to each innovation and perhaps even assessing a scale for the level of their contribution related to royalty payments makes the following royalty distribution process a simple algorithm.

b. Upon a medical innovation going through the entire development process and achieving the desired result of becoming a royalty producing medical

innovation, the Aegis fund can then tap into the IP blockchain and determine who should receive royalty payments. Since some of the royalty payments may be going to companies and other payments maybe going to individuals or to universities, the only determination required by the Aegis fund is that a certain wallet or private key and public key combination contributed along the process of a particular medical innovation to help introduce it into the marketplace. The complexity of exactly who owned that wallet is left up to either the business, the individual, the family, or the trust etc. that the wallet can be legally accessed by or assigned to.

c. With complete verification and tracking of the entire innovation development process from concept to final market introduction all immutably recorded on the blockchain with cryptographically secured signatures, there are no opportunities for conflicts regarding who contributed a particular idea. This translates into royalty payments and distribution following a preordained, conflict free, legally recognizable and community verifiable allocation method. As opposed to the current process where intellectual property can be claimed by a variety of sources without any uniform method of determining who was the first to achieve a patent worthy innovation, who had the most important contribution, or whether or not there is a valid claim or invention at all. These issues that have been perennially fought in court or via lawsuits ideally would no longer be a factor. Realistically, patent conflicts will persist though they can be minimized by the IP blockchain to only esoteric questions of interpretations rather than ownership. The IP blockchain puts a time and identity stamp on every single contribution that the entire community can be made aware of at any time without exposing the innovation to copycats or being stolen. This feature alone can negate the bulk of legal challenges, allowing innovations to proceed without the stifling financial burden of eventual legal defenses.

d. There are a variety of ways to achieve an equitable distribution of royalty payments along with the credit for developing the medical innovation, but the simplest method is to use smart contracts riding on top of colored coins

that contain the data describing the innovation. The data that each colored coin, or non-fungible token contains can either be the actual engineering and patent information as well as the particulars of each contributor, or it could simply be decentralized data pointers that are cryptographically hashed to prevent hacking or changing the data, and that point to a distributed or decentralized database that is also immutable. Since blockchains do not function well with large volumes of data including video files, CAD files or even large text files, the preferred method to execute an IP blockchain is embed hashed pointers to either the IPFS, LBRY, Storj, Filecoin or a similar decentralized database that is universally acceptable and universally accessible within the development network.

e. The highest level of functionality and utility for this IP blockchain that transfers the data to the Aegis fund, is that the manufacturing and sales of a particular medical innovation would also be tracked via blockchain. This added functionality is entirely possible and easy to implement with serialized production for medical devices. It enables instantaneous accounting and traceability for each product so that those that are supposed to receive royalty payments do not have to wonder whether or not they are being short changed. Having royalty payments short changed or lost in suspicious expenses or false sales numbers is so common in industry as to be almost an accepted practice. No longer will that be the case with a fully integrated intellectual property blockchain feeding IoT data without lag into the Aegis fund. This arrangement will also allow for distributing royalty payments with serialized tracking of each product that leaves the manufacturing floor and goes to distributor and is then delivered to an end customer. This would trigger automatic royalty distribution with no accounting and no financial engineering involved other than the smart contracts, and perhaps the Internet of things. The interface between the real world of delivering a medical device and the software world of distributing tokens that are fungible into fiat currency or some other form of value would run virtually without human intervention.

Vertu IP Tracking Blockchain Process Diagram



Vertu IP Blockchain Token Functionality



Vertu Blockchain Integration



4. Vertu IP Blockchain Token flow.

1. Either a single or team of innovators generates a concept for a new medical device or other form of technology known as X1 at Version1, or X1V1.

2. The developers submit the innovation per a Vertu IP blockchain format for submission to the blockchain smart contract.

3. The Vertu IP blockchain issues an NFT (non-fungible token) that is only accessible and transferable by the private key holders for the wallet that receives the NFT per the smart contract wallet address submitted in step 2.

4. Either a new member joins the development team, or the same development team further enhances their initial concept. The team now submits an updated version of the X1 innovation, now at Version 2, or X1V2.

5. The Vertu IP Blockchain automatically links the first NFT X1V1 to the new NFT X1V2. The NFT X1V2 also has pointers to the originating NFT X1V1. This internal reference system between the NFT's allows for tracking the innovation either forwards or backwards from the time stamped NFTs.

6. Each member of the team can submit innovations separately if the team decides to enable this functionality. Otherwise, the team must submit all innovations together by use of jointly held private keys.

7. All supporting designs, research, analysis, and technical developments can be linked to the relevant NFT via embedding the data in the Vertu IP blockchain or by use of pointers to a cryptographically secure storage network.

8. The last stage of development creates the Vertu IP NFT-Final that allows for locking the design and development cycle to submit the innovation for funding and regulatory approval.

5. Aegis Fund and assessing new technology

a. The Aegis Fund will be comprised of primarily medical personnel along with financial experts that allocate funds for the VIP, the intellectual property already developed by Vertu Medical, and potential external business opportunities aligned with the values of Vertu Medical within the healthcare arena.

b. Seed funding sources for the Aegis Fund includes future revenue from the medical innovations donated by Vertu Medical, proceeds from the IEO and STO raises, and

qualified investors wishing to eventually receive dividends from Vertu Medical's businesses. There will also be a segment of fund raising for specific research and development targeting particular diseases or conditions, to allow for charitable donations.

c. Fund managers, including medical professionals, will meet and decide on the priority of innovations from the Vertu network as well as external innovations, or medical businesses that are considered worthy for fund allocation. The primary decision criteria regarding which projects will receive funds include patient impact, development cycle, potential return on investment, and breadth of application.

d. Fund allocations could be in the form of Aegis tokens that represent a claim on the fund's net asset value. This method would only function once the Aegis token achieves some level of fungibility with either an exchange that can convert the Aegis token into fiat or recognition among the VIP and investors that the token must be held for a period of time before it gains fiat value.

e. After the initial fund allocation of perhaps 3 -5 years to allow for the initial 10 medical innovations to get to market and receive royalty payments plus time for raising capital through a series of rounds, Aegis will begin distributing dividends based on the income from the various innovations and business segments. Considering that almost all the initial 10 medical innovations will be entering markets with an aggregate value in the many billions of dollars, the size of the Aegis fund and the subsequent dividend payments could be many times the initial investment in tokens by fund participants.

Insight

The above section clarifies how the Aegis fund helps convert innovations into profitable enterprises. Investors that buy Aegis tokens will potentially gain high dividend flows as the innovations and outside investments produce returns on capital. The following section clarifies how token royalty distributions work.

6. Token royalty distributions

a. As explained above, token royalty distributions can take the form of additional Aegis tokens or Vertu development network tokens, or a variety of other tokens that ideally will achieve conversion into Bitcoin, Litecoin,

Ethereum or directly into fiat currency including USD, EUR, CHF, GBP and others.

b. Royalty distributions could easily flow through a smart contract that sends a certain percentage of each royalty payment for a respective medical innovation to the contributors via an automatic schedule either monthly, quarterly, semiannually or annually. The smart contract could easily be verified for validity through community inspection so that each royalty payment is verified for accuracy. There does not need to be an accounting examination to ensure that all the royalty payments have been adequate distributed.

c. While the royalty payments could be made through tokens, smart contracts are currently able to also transfer funds electronically outside of the blockchain using ACH or Swift or some other banking mechanism. The entire royalty payment for innovations can be made fully automatic and hands-off so that the accuracy is insured, the timing is insured, and the accounting records are immutable.

d. If instead of seeking royalty payments, a fund investor or potentially even a medical innovation contributor would like to increase their level of ownership in the Aegis fund or even the VIP, then the royalty funds that would otherwise flow to that investor or to the medical innovator, can be allocated to buying more shares in the Aegis fund or tokens. The user can even selectively allocate towards particular projects, funding the medical innovators project, or potentially an investor's business project. This important capability is similar to reinvesting dividends either in mutual funds, ETF's, or a stock. By reinvesting the royalty payments of dividends, the investor or the medical innovator gains a larger percentage of future rewards. This also means that a medical innovator could potentially fund their entire investment in the Aegis fund simply by contributing through the Plexus network to projects that gain market acceptance, go through the FDA approval process, and then achieve royalty payments.

Insight

As the preceding five sections explain, VMT offers a plethora of profit producing business silos from the initial 10 healthcare innovations to the Vertu Innovation Platform, the Vertu IP Development Network, and the Aegis Fund. Section 6 explains the potential life-changing wealth these high value add business silos are capable of generating for VMT investors.

7. Investment and Business Opportunity

A. Royalty payments from the Alpha Group of 10 patent pending innovations



According to a July 2017 report from Grand View Research, the surgical instruments and equipment market is anticipated to reach a value of $20.3 billion by 2025. The $20.3 billion dollar revenue value is just the beginning for one of the innovations already part of Vertu Medical's innovation bank. Another potential patent deals with a sleep apnea device that will eventually enter a market valued over $8.15 billion in 2018 and growing at 6.8% according to Grand View Research.

Considering that many of the 10 medical innovations contributed by Vertu Medical involve surgical instruments or healthcare equipment, the potential business opportunity for all 10 patents could reasonably be expected to achieve hundreds of millions to more than a billion dollar in yearly revenue.

Just these two patents alone are already tapping into markets that are worth approximately $30 billion.

Extrapolating from these cases and being conservative, one could say that each medical innovation might realistically achieve a 5% market penetration level in their respective markets that offer a potential on average of $5 billion in annual revenue.

This estimate translates to $250 million per innovation. With 10 innovations initially contributed by Dr. Morris and as many as 90 available, this stack of innovations could represent future revenue of $2.5 billion USD as follows.

For the potential investor considering why one might want to participate in the IEO or STO with Vertu Medical, one of the primary reasons involves the 10 high value medical and healthcare innovations created by Vertu Medical. Essentially, by investing at this point prior to these innovations achieving full patent status and entering the market, the investor is getting a rock-bottom price on a potentially extremely valuable enterprise that will likely produce long-term and growing royalty payments or dividends.

B. Aegis Fund allocation strategy, dividend payments, and management method

a. The Aegis fund will focus on medical and healthcare technology because that is the province of the founder as well as several of the core investors of

Vertu Medical. The level of expertise developed over a 38+ year career in emergency medicine and trauma allows Dr. Dennis Morris; founder of Vertu Medical Technologies LLC, in coordination with the Vertu Innovation Platform (VIP) providers, to assess healthcare and medical device improvements with the level of knowledge that will ensure above market returns.

b. Though the medical professionals steering allocation decisions will play the deciding role in terms of a medical devices potential, financial experts on the allocation board will round out the business analysis to determine if the medical devices can provide a return on investment sufficient to meet the funds goals.

c. Considering that medical devices can take from a minimum of six months to get FDA approval to possibly years for the approval process of a Class III medical device, the fund must stage allocations to ensure both early and future returns. After just one of the 10 projects that seed the VIP eventually provides royalty payments to the Aegis fund, the fund can take a long-term investment horizon of 3 to 5 years for developing both Vertu medical innovations and external business opportunities.

d. As mentioned previously, dividend payments can take the form of either tokens, if those tokens are convertible into fiat, or direct fiat currency payments. Since the Aegis fund will probably form as a specialty fund in the medical device arena under a Closed End Fund (CEF) format, there will be a restricted number of tokens issued initially, each entitling bearers of the tokens to dividends from the funds operating income.

e. Operating as a Closed End Fund (CEF) will allow the Aegis tokens which could be thought of almost as stock shares, to become valued higher than the net asset value or even lower than the net asset value depending on the rate of return for dividends and investor sentiment. The ideal scenario would be the CEF Aegis token, representing essentially the right to receive royalty payments, becomes valued at the net asset value of the fund plus the annuitized royalty payments with a market premium based on the relative performance of the fund compared to its peers or market indexes.

8. Vertu blockchain applications and licensing

The VIP will rely on the Vertu or VIP blockchain to originate, track, process, develop, and finally introduce medical innovations. The following explains the potential implementation of this far-reaching application for blockchain technology.

a. While every member of the VIP will be required to use the Vertu IP blockchain, the blockchain can also be used by external parties paying a software as a service fee (SaaS). The potential income from this IP blockchain application could become significant because the market for documenting innovations and automatically moving the data is a multibillion-dollar industry. While not exactly product data management software, similar market metrics apply suggesting total potential U.S. revenue over $2.5 billion for innovation development systems.

b. The Vertu IP blockchain could run on a variety of platforms because speed and transaction time is not critical. The most likely platform will be EOS because of the ease of integrating with a variety of other applications that could feed data into the EOS based Vertu IP blockchain. EOS can be tailored in C++ enabling rapid development, easy API's that integrate CAD, CAM, time tracking, accounting, human resources, and other corporate systems that can produce innovation reports directly from the Vertu IP blockchain.

c. The Vertu IP blockchain token will be strictly a utility token until it processes through for FDA approval or market introduction. Once a particular innovation that is tied to a token or connected tokens achieves market introduction, then the system would rely on a smart contract to port the innovation into the Aegis fund framework or another framework that will allow for financial transactions to take place. This arrangement simplifies the development and use of the Vertu IP blockchain. While it defines what the royalty payments will be, it does not actually process those payments.

d. Main components of the Vertu IP blockchain include: a Testnet, a Mainnet, a wallet, and smart contracts that enforce innovation ownership, joint development, a process of moving an innovation from one step to another step i.e., from design to analysis, then to prototyping, and potentially to production, APIs for linking product development systems to record initial access and final submission of files, and potentially, Internet of Things access to link with manufacturing tracking. Fortunately, EOS is well-equipped by virtue of its extensive C++ library to integrate with almost any type of product management software, product development software, inventory management software, and even accounting software. This interoperability allows the Vertu IP blockchain to serve as a focal point for tracking the entire lifecycle of an innovation from concept through manufacturing, distribution, and delivery to a client.

e. The primary protocol standard employed by the Vertu IP blockchain will likely be the dGoods NFT specification recently created for EOS. The ERC

721, or the more advanced ERC 1155 specification, could also be used though the Ethereum blockchain is severely rate limited and more challenging to integrate into hospital corporate operating systems.

9. Collaborative Endeavor Opportunities (C.E.O.)

The C.E.O Network offers full-service business management, product development resources, logistics, manufacturing, and project management. Think of the Vertu Innovation Platform as the research and development arm of VMT with the C.E.O as the engineering, analysis, design, packaging, logistics, marketing, distribution, customer service, and business management arm handling commercial delivery of products.

The CEO network can develop Plexus innovations and completely manifest them through in-house engineering, analysis, testing and manufacturing, ultimately leading them to market. This same level of service could be applied to software concepts or other healthcare initiatives where medical industry and product development expertise is required to deliver some new service or product to the market.

a. The CEO Network can serve as a fully aligned participant with the Vertu Innovations Platform to do the heavy lifting of engineering, analysis, CAD/CAM, manufacturing design, prototyping, and testing that hospitals and healthcare institutions are not set up to handle. Because the CEO Network will be within the Vertu Medical umbrella of companies and intimately familiar with products developing through the VIP, it will be in the best position to provide these high-level services.

b. The CEO Network does not require access to the Vertu IP network, though it certainly can interface with it. One could imagine that the CEO network serves a similar role as a machine shop, an engineering firm, or a testing firm would to any other development project. While the CEO Network works on the project, it is not necessarily developing the innovations for filling the vision of the innovator. On the other hand, it is possible that the CEO Network and the engineers and software developers operating within it could partake in the Vertu IP blockchain as contributing innovators. In either case, the main value add is that the CEO Network becomes a profit center for Vertu Medical that aggregates and distributes product development costs among the VIP members. This will allow for dramatic economies of scale so that the thousands of Vertu innovators can produce new products without having to be overly concerned about the engineering costs required for each innovation.

c. In addition to serving as the managerial and product development expertise for the VIP, the CEO network can also participate in outside business activities sharing the managerial and product development expertise with the free market.

d. Without the CEO Network, the VIP would struggle to move from the conceptual phase to prototyping and engineering, analysis, testing, etc. These critical steps will not be a problem because the CEO Network will provide a seamless framework for the IP from the VIP to transition into reality through the challenging steps of engineering all the way through manufacturing. Together, the VIP and the CEO Network form an idea and product generating framework that lifts the burden of skills that medical professionals will typically not possess and allows them to focus on creating medical innovations where they can focus their expertise.

e. The CEO network may also provide managerial and operating expertise to any of the Vertu medical innovations once they reach the market or it can

support Aegis fund investments in high potential businesses. Providing managerial expertise and operating expertise is common practice for venture funds or highly specialized investment funds that are supporting companies that require specialized technical knowledge or extensive operating experience in order to reach the market. Considering the decades of experience in the medical arena from the founders of the CEO Network, it is a natural fit for them to be able to lend operating and managerial expertise for any of the companies that have signed royalty agreements for Plexus intellectual property or even businesses requesting funding from the Aegis fund.

Insight

Though the product manufacturing services the C.E.O division of VMT offers is widely available in the form of job shops, specialist design firms, and logistics concerns, the C.E.O. will be uniquely position to offer all of these functions under one umbrella with a deep understanding of the healthcare market. The existing product development firms cannot handle end-to-end product delivery as the C.E.O. is designed to do.

10.Token Application and Economics

A. Platform: EOSIO blockchain with dGoods NFT token basis

a. The development teams behind EOS released the Non-Fungible Token standard called dGoods in 2019. Non-fungible tokens allow for carefully identifying the owner of a particular item in the form of a title. The famous use case for non-fungible tokens called Crypto Kitties showed images of unique avatars that were linked with ERC 721 tokens that each obtained a unique value based on the appearance of the Cryptokitties. Simply stated, each token was the title to the Cryptokitties in the form of a smart contract.

b. There are a variety of ways to implement the IP blockchain using the EOS NFT standard. One potential method is that the initial innovator or innovators for an idea go through the trivial process of filling in a formatted smart contract that creates a dGood or NFT token on the Vertu IP Blockchain. The innovator or innovators then interact with this new token by linking it to its further development in the form of another new token. So, the same idea or innovation moves through a series of token stages until it finally evolves into the product that is introduced into the marketplace. EOS's dGoods protocol allows for creating both fungible and nonfungible tokens in a replicated fashion so that they all remain under one umbrella. In this case, that one umbrella would be the main innovation concept.

c. After the innovation proceeds through a series of iterative steps towards its finalized form, it then becomes another non-fungible token that can be locked down to enter into an Aegis contract and transferred into the royalty distribution system. This sequence of transferring the VIP token into the Aegis fund token for royalty distribution enables two important features. First, the innovation will be tracked with the Vertu blockchain as solely a utility token like a standard ERC721 token. Once the VIP innovation associated with a Vertu token achieves royalty status, it becomes part of the Aegis fund and bound to a security token on the Aegis blockchain.

d. It is possible that as an innovation token moves through the process towards development it could potentially gain value because it's operating as essentially an option on future royalty income. While this is not intentionally designed into the utility of the Vertu token it is foreseeable that potential investors may want to work with the Vertu IP network in order to determine which of the future innovations could produce the greatest royalty and get an early bid on the associated Vertu token.

e. Because there will be nonstop generation of innovations that are tracked on the Vertu IP blockchain, token distribution will be an ongoing process. Each token representing the initiation of the concept or innovation will gain or lose potential value simply based on the concept tied to the token and without market impact from the Vertu token network. Just like the Cryptokitties platform has kitties of widely varying value, the same thing might occur with Vertu IP blockchain.

f. The wallet for the Vertu IP blockchain will be used to store the tokens that represent concepts or innovations or even finished products. The wallet portfolio will simply show all the innovations in the form of tokens that the wallet owner has contributed to or has a part of along with where they are in the entire process. The wallet will also have a tracking function that shows the original token that propagates into other tokens as the healthcare innovation matured and went through development cycles. The result would be a list of tokens that mark each development phase of the medical innovation from initial concept all the way through FDA testing into the final marketable product.

g. The advantage of tracking each stage of the innovation with a separate token is that it allows for creating multiple innovations starting from initial concept as well as dramatically changing how the innovation manifests while it goes through the iterative development process. It would seem simpler to have one token representing one idea and simply modify that idea still tied to the same token. The problem with that is the issue of creating multiple different developments all tied to the same concept, a common occurrence in product development cycles. The multi-token format specified here for the Vertu IP development blockchain allows for one concept manifesting into multiple different varieties and each one of those varieties can then be independently developed by different contributors all the while staying under the umbrella of one innovative concept. While this is a more complicated system, it is also more amenable to working with a large group of developers and multiple offshoots of the same conceptual idea.

11. Vertu Medical Organization Token Internal Application

The diagram below shows how one business entity within the Vertu Medical group of companies works with another entity and how the Vertu IP network integrates with CEO and the Aegis fund.


Vertu Medical Group of Companies
Aegis Fund
Plexus Development Network
CEO Network
Plexus IP Blockchain SaaS
STO Funds
IEO Funds
Royalty Income
Distribute Dividends
Funds to Plexus Projects
Funds Businesses
Uses AFT Token
Generates Innovations
Coordinates
Records
Feeds CEO
Tracks
Uses PLX Token
Supports Plexus
Develops Innovations
Offers Management
Dvelops Businesses
Tracks all PDN Activities
Income Source from PDN
Income Sourse as SaaS
Feeds Royalty System
Uses PLX Token
Feeds Aegis w/Royalty Innovations

Vertu Innovation Network



12. Prospective Token Value Increase



13. Tokenomics

Vertu Medical will employ blockchain technology in two separate formats. The first format will be for the VIP using the VIP IP blockchain for tracking innovations from beginning to end. This token will be strictly a utility token, much like a game token being used within a virtual reality game.

The second format or implementation will be for the Aegis fund to distribute royalty payments and allocate investment funds based on an STO oriented token. This token will grant the holder of the token or investor in the Aegis fund access to dividends or royalty payments based on successful market introduction of the innovations from the VIP as well as the original 10 innovations from Dr. Dennis Morris and the CEO network business activities as well as outside investments.

A. Vertu IP Blockchain Tokenomics

Classification: Utility token

Full Name: Vertu IP

Token Code: VRT

Initial issuance: 100,000

Protocol: EOS dGoods

Network: Private, distributed among Vertu members.

Confirmation: DPoS

Speed: >3,000 TPS

Confirmation time: <0.5 seconds

Development language: Primary, C++

Limit of Issuance: None.

Original Value: Non-Fungible. No assigned value

Servers Required: 21 distributed. Can be modified.

Initial distribution: None. Token emanates upon an innovator registering a Concept and issuing a dGoods token representing the concept.

Total Issued: Unlimited.

Rate of Issuance: Per Vertu Innovators Network requirements. Unlimited.

B. Aegis Fund Token:

Classification: Security Token

Full Name: Aegis Fund Token

Token Code: AFT

Initial issuance: 1,009,003,247

Protocol: ETH or EOS standard

Network: Public, distributed qualified investors, developers, and Aegis Fund

Confirmation: PoS or DPoS

Speed: > 25 tps

Confirmation time: <10 seconds

Development language: Solidity or C++

Limit of Issuance: 1,459,003,247

C. Token distribution:

Initial sale – 15%: 151,350,487 AFT
Bonuses – 10%: 100,900,325 AFT
Retained by Aegis Team – 12% (6-24-month lock-up period): 121,080,390 AFT
Retained for Funding Allocation – 63%: 100,900,325 AFT

D. The CEO Network Token

The CEO may also employ tokens to distribute costs for product development. If the token requires fiat conversion, it may use the AFT for assigning costs and capturing payments among the Vertu network. Since the CEO Network is not oriented towards paying dividends nor distributing royalty payments there is no need for it to be a security token. It may as well function as a utility token simply to allocate time and expenses among the different members contributing to a particular project or innovation in the Vertu network and use it as a form of an accounting system. If this is the case, then there would probably be a limited number of tokens assigned to the CEO network for use in accounting for time and expenses per project. The more likely scenario is that the Aegis fund token or AFT will serve as both the tracking and the fund distribution or money distribution token within the CEO network.

14. Use cases

Investors:

Purchasing AFT entitles investors to receive dividends based on the success of innovations from the Vertu network, profits from the CEO services division, medical sector investments, and general ROI from the business activities of Vertu Medical. Dividends can be paid in either AFT or fiat once the project achieves convertibility.

Once AFT achieves fiat convertibility via exchanges and pays dividends from cash flowing innovation or investments, AFT can eventually reach a stable coin status based on historical ROI (return on investment) and Net Asset Value of the fund.

Vertu Innovation Network:

The VRT token is designed to function only within the Vertu IP network. Though VRT may achieve convertibility through exchanges, the primary intention and function of VRT is as a tracking token to link innovations to the people and organizations involved.

Aegis Fund:

AFT will be the primary tracking and dividend distribution method for the Aegis Fund. As AFT achieves convertibility to fiat, Aegis will be able to broaden investment activities to include funding promising medical research, serving as an angel investor for small medical start-ups, as well as continuing to fund Vertu innovations. The AFT value and convertibility will be critical to providing Aegis the liquidity to engage in the core activities necessary for generating ROI.

15. Roadmap

Q4 2022

Fund Raise: $1 mil

Activity: Form core management team for Vertu, CEO, and Aegis Fund divisions

Begin Vertu IP blockchain development

Move most promising innovations through approval to royalty agreements.

Establish Aegis Fund board, Chief Investment Officer, criteria, and disbursement fund accounts.

Q1 2023

Fund Raise: $3-5 mil

Activity: Vertu IP blockchain alpha phase testnet for linking all Vertu nodes, recording innovation input, linking innovations, retrieving data, and transacting.

Complete testing for at least one innovation and introduces to potential marketing partners

Initiate Aegis Fund investments for Vertu Innovation Platform, medical sector businesses, and CEO activities

Begin offering CEO services to Vertu network partners and external companies

Q3 2023

Fund Raise: $5-15 mil

Activity: Complete Vertu testnet and mainnet. Complete beta protocol for actively using the Vertu IP blockchain within a small portion of the Vertu network. Set roll-out date for market introduction as a U.S. centric IP blockchain.

At least one innovation achieves market introduction and begins generating royalty payments for the Aegis Fund. More innovations move from conceptual to prototype, testing, and approval stages.

Aegis funds innovations, produces dividends from previous medically oriented investments, funds more innovations, seeds medical start-ups, begins paying dividends to AFT holders.

The CEO services division provides conceptual to production manufacturing and management support for innovations now with linked suppliers and in-house assembly, testing, and marketing functions.

Q2 2024

Fund Raise $15 - $100 mil (if necessary)

Activity: Vertu IP blocknet branches to global access in the key major languages of innovation centers (China, U.S., Japan, South Korea, Eurozone, Germany, Russia, India, Canada, Brazil).

Multiple Vertu innovations reach market introduction, producing a growing stream of royalty income of an estimated $XX million per year.

The Aegis Fund continues paying dividends, supporting Vertu network innovations, venture funding medical start-ups, and appreciating assets under management to return an increasing dividend to AFT holders.

The CEO services division expands in-house manufacturing capability, logistics, and management as the Vertu network continues feeding innovations through the CEO business building process. CEO services will be cash flow positive.

16. Vertu Medical Technologies Concept

Dr. Morris describes the concept of Vertu Medical Technologies to be a product realization company providing novel, disruptive solutions for the healthcare innovation industry. Through proprietary Collaborative Endeavour Opportunity negotiations (C.E.O.s) Vertu Medical has created an expanding innovations enterprise for generating a perpetual pipeline of healthcare innovations. Vertu Medical Technologies has positioned itself to soon become a worldwide leader in medical device technologies through the company's proprietary acquisitions platform. The company strives to provide broad spectrum solutions to present day problems in the healthcare sector.

Having identified and defined the known genesis of numerous major global healthcare concerns and shortcomings, Vertu Medical has created the means and methodology to address each identified problem with a proactive solutions program. Employing this disruptive solutions program, the company is additionally positioned to rapidly expand its problem-based applications into many additional sectors.

17. Vertu Medical Technologies Financial Model

Vertu Medical Technologies business strategy has been programmed for success. By prioritizing and grouping our Innovation Projects according to development maturity while limiting the number of projects that will be addressed at any given time, VMT intends to fund operations and disseminate dividends and royalties on a project by project basis. Therefore, VMT has based its start-up financial model solely on the first project of the ALPHA GROUP of 10 projects; the Surgical Instrument Technologies.

The Surgical Instrument Technologies project will provide the means for VMT to soon market a complete line of improved surgical instruments that utilize locking mechanisms to perform their function. This portfolio of nearly one hundred instruments, with its many advantages over conventional art, is projected to soon dominate this global division of surgical instruments.

Reiterating a July 2017 report from Grand View Research, the surgical instruments and equipment market is anticipated to reach a value of $20.3 billion by 2025. The $20.3 billion dollar revenue value is just the beginning for this single innovation already part of Vertu Medical's innovation bank. Another potential patent deals with a sleep apnea device that will eventually enter a market valued over $8.15 billion in 2018 and growing at 6.8% according to Grand View Research.

Extrapolating from these cases and being conservative, one could say that each medical innovation might realistically achieve a 5% market penetration level in their respective markets that offer a potential on average of $5 billion in annual revenue.

This estimate translates to $250 million per innovation. Conceivably, with the 10 innovations initially contributed by Dr. Morris and as many as 90 available, this stack of innovations could represent future revenue of $2.5 billion USD yearly.

For the potential investor considering why one might want to participate in the IEO or STO with Vertu Medical Technologies, one of the primary reasons involves the 10 high value medical and healthcare innovations already created by Vertu Medical. Essentially, by investing at this point prior to these innovations achieving full patent status and entering the market, the investor is getting a rock-bottom price on a potentially extremely valuable enterprise that will likely produce long-term and growing royalty payments or dividends.

The savvy investor may readily appreciate that with the propagation platform that VMT has constructed for Innovation Projects, the investor will have a cumulative portfolio of dividends and or royalties amassed in perpetuity.

Key Performance Indicators

The Key performance indicators (KPI) for Vertu Medical Technologies show that:

1. Total Shareholder Equity begins going positive around Aug-2020, reaching $2M by May 21, less than 18 months after startup, reaching almost $12M by 2024.

2. Operating Cash Flow will be more than sufficient to fund product and business expansion starting approximately 24 months from start-up. The new business segments will lead to enhanced shareholder value beyond that already shown in the charts of the expanded Financial Model linked below. The charts show just the core surgical instrument business segment value. Funding new product development will generate multiple income streams.

3. Unlevered Free Cash Flow exceeding $1.5M starting Y2022 and reaching $4.5M by 2023 will ensure long term business viability for the surgical instrument division and fund development of the Vertu IP Blockchain platform.

4. Terminal Corporate Value based off of only the initial surgical instrument business segment reaches almost $38M by 2024 using ultra conservative sales estimates.

18. VERTU MEDICAL TECHNOLOGIES IEO TEAM BIOS

ABOUT THE FOUNDER:

Dr. Dennis Morris, M.D., founder of Vertu Medical Technologies, defines Virtue as;

"An application of servitude toward mankind in such a manner to be recognized by one's peers as morally righteous and good. Achieving such recognition must be self-sought and undelivered and obtained by restraint, wise choices, respect, perseverance and diligence. Virtue is therefore an achievement of discipline appreciated by others and not a reflection visible unto oneself. Virtue is a quality and manifestation of good deed and laborious intent and permission for all God given innate goodness to prevail. In one's journey virtue is the emanation of performance resultant of the efforts of perpetual benevolent resolve".

At the age of five, Dr. Morris committed to the medical profession dedicating his life to help others and at the age of seven purchased a statue knowing quite well that one day it would bear symbolism to an innate drive to serve through innovation and defend those less able. It is this same statue that Dr. Morris integrates the merits of virtue with the perseverance to endure the adversities of life.

With decades of dedication to the medical profession Dr. Morris developed breakthrough solutions to numerous existing healthcare problems while appreciating that the conventional system of intellectual property protection and product development was a flawed system. Realizing that a better system could be developed, Dr. Morris worked to reengineer the means and methods to govern and protect intellectual property rights while realizing, through innovation, a problem / solution mechanism to include a global pool of individual innovators.

Through selfless devotion, Dr. Morris has created a novel and perpetual means for a similar minded network of healthcare providers and managerial professional innovators to address existing and future healthcare issues as a coordinated team, providing a better system for IP protection and team product realization. With the tenets of virtue in mind, Dr. Morris delayed introducing his comprehensive portfolio of nearly ninety intellectual properties until maturing an improved means of property protection and innovator participation recognition.

With the introduction of the proprietary Vertu Medical Technologies systems presented herein, Dr. Morris has donated the entire compendium of intellectual property to the Vertu Medical Technologies company in order to value the construct and provide the means for a successful venture. An initial group of ten transferred intellectual properties (Alpha Group) consists of projects with the highest degree of maturation dedicated to providing a sustained capital foundation for the company. As the architecture of Vertu Medical Technologies is realized, the Morris Foundation has provisions for additional groups of ten projects (the Alpha - Omega Concept) to be transferred into Vertu Medical's prioritized project portfolio. In this fashion, Dr. Morris's intellectual properties alone will provide a decade or more of innovation and the construct of Vertu Medical Technologies is such that a global innovation network will eventually supplant the project propagation pipeline.

Through a sibling philanthropic foundation established by Dr. Morris; the American Society of Chief Executive Officers, Vertu Medical will endeavour to work in concert with other world class research and development organizations for the benefit of all. This non-profit subsidiary of Vertu Medical Technologies has been created by Dr. Morris to integrate with other global foundations to provide and facilitate healthcare assistance for the underprivileged and needy. As Dr. Morris humbly puts it;

"Weather the storms calmly in life, develop strength through kindness and good heart, be honorable by treating others honorably and be remembered for what good you have done for others".

19. Team Leadership

Name: Dr. Dennis J. Morris, M.D.

· Title: Founder, CEO and majority owner of Vertu Realities LLC.

· Title: Founder of Vertu Medical Technologies LLC.

· Title: Founder and Board Member AACEO (American Association of Chief Executive Officers)

· Title: Founder and CEO of Vertu Athletics

· Title: President of Vertu Society

· Title: Founder and CEO of Prescribers Direct Rx

- Key Functional Areas Covered: Head of Innovations Division, Board Member Vertu Realities LLC, Board Member AACEO, Chairman of Project Determinations and Acceptance Committee, Head of Research and Development Division.

- Past positions, successes and/or unique qualities: Thirty eight year tenure as Emergency Medicine Physician, Hospital Executive Committees, Quality Assurance Directorships, Emergency Department Medical Directorships, Medical Director of EMT programs, Theoretical Cosmologist, lifetime practitioner of Martial Arts, Black Belt Japan Karate Association, former World Class javelin competitor, inventor with extensive portfolio of medical and non-medical device Intellectual Properties, member Kappa Alpha Fraternity

- Educational background: LSU – Baton Rouge, Louisiana undergraduate, McNeese State University – Lake Charles, Louisiana graduate; Premed, Mathematics with Computer Science Curriculum, graduate LSU School of Medicine; Shreveport, Louisiana, Internship, Residency with LSU, Board Certification.
- https://www.linkedin.com/in/dennis-morris-936b1015

Name: Mark Solomon

- Mark Solomon began his career in engineering and R&D for firms including Texas Instruments and Rand.

- Mark transitioned to becoming a licensed financial adviser, commodities trader, online marketing consultant, and author of multiple financial books including one of the early books about Bitcoin.

- Mark has also led the content development for technical and financial consultancies.

- Recognizing the global potential of Vertu Medical Technologies, Mark is now advising VMT in marketing and technical expertise with the intent of growing the company into a multi-billion-dollar, global enterprise.

Dr. Richard A. Foster, M.D.

· Title: Board Member and minority owner of Vertu Realities LLC.

· Title: Board member of AACEO (American Society of Chief Executive Officers)

· Title: Interim CFO of Vertu Realities LLC.

· Title: Medical Coroner of Tangipahoa Parish of Louisiana

· Key Functional Areas Covered: Advisory Board member of Vertu Realities LLC, committee member of Research and Development Division of Vertu Realities LLC, Project Determinations and Acceptance Committee member

· LSU graduate Premed, LSU Medical School of New Orleans, Louisiana, Board Certification Emergency Medicine.

Name: Taylor E. Morris

· Title: Chief Operations Officer for Vertu Realities LLC

· Title: Regional Project Director for Vertu Realities LLC

· Title: Marketing Director AACEO

· Title: IEO Private Sale Management Director

· Key Functional Areas Covered: Coordination and oversight of regional project management, operational manager for Vertu Realities LLC, member of Project Determination and Acceptance Committee, member of the Advisory Board, IEO pre-sale management, escrow and custodial advisory.

· Educational background: LSU – Baton Rouge graduate, Bachelor of Science degree in Finance.

linkedin.com/in/bo-morris

Name: Joey Giluso

· Title: National Project Director for Vertu Realities LLC

· Title: Community Management IEO Director

· Key Functional Areas Covered: Coordination and oversight of National project management, member of the Advisory Board for Vertu Realities LLC, IEO Social Media and Community Management Director, computer and telecommunication expertise.

· Former owner and CEO Intelecom Technologies, US Karate Team member 1999 - 2007, 3-time US Team Gold Medallist in International competition, 3 time US National Karate Champion, US Karate National Team Coach 2017 – present, 6th Degree Black Belt of prestigious Karate Association of Japan, Board of Directors Japan Karate Association American Federation. https://www.linkedin.com/in/joey-giluso-a5676a68/

Name: Richard Richardson, Esquire

- Title: Legal Counsel for Vertu Realities LLC.
- Title: Board Member AACEO (American Association of Chief Executive Officers)
- Key Functional Areas Covered: National Director of Legal Department for Vertu Realities LLC, Advisory Board for Vertu Realities LLC, Advisory Board and Legal Compliance Officer for AACEO and CEO Vertu IEO.
- Specializing in Corporate Law, Tax Law, Estate Planning· LSU and A. and M. BS graduate; Prelaw, LSU and Georgetown Law Schools graduate JD, induction

20. Fundraise: Budget Allocation



- Research & Development 40%
- Operations & Corporate Development 35%
- Marketing 15%
- Floating 10%

Fundraise: Token Distribution



- **Fund Allocating** **63%**
- **Initial Sale** **15%**
- **Aegis Team** **12%**
- **Bonuses** **10%**

21. Summary

Vertu Medical is delivering high impact technological advances to the healthcare industry with correlated and potentially life changing financial returns for investors.

As detailed in the previous sections, Vertu Medical will deliver market leading offerings in four main business divisions:

- The Vertu Innovation Platform (VIP) seeded with 10 innovations from Vertu Medical
- The C.E.O. (Collaborative Endeavor Opportunity) Network (CEO)
- The Aegis Fund with a Charitable Component (Aegis)

- The Vertu Intellectual Property Development Blockchain (VIP)

The divisions support each other under a profit center model for joint product and business development projects.

Here is how Vertu Medical's divisions work together towards successful healthcare product and business creations.

- The VIP coalesces healthcare providers into a potent medical innovation generating team.
- VIP members use the VIP for logging innovations from concept through the final iteration prior to market testing or regulatory approval. The VIP will eventually replace all patent application and tracking systems world-wide.
- Each VIP member has access to the C.E.O. services plus management for innovation engineering, testing, prototyping and analysis for projects.
- Aegis determines which projects to fund from the VIP, allowing those projects to pay for C.E.O. services required for full market introduction.
- Investors who participated in the Vertu Medical IEO or STO and hold Aegis tokens, receive payments from the royalties and returns from businesses generated by the VIP, C.E.O., or external investments from Aegis.
- VIP members receive royalty payments automatically based on smart contracts running on the VIP and Aegis blockchains that define each innovators contribution to the project earning royalties.

21. Benefit of Vertu Medical's Integrated Development Businesses

Healthcare innovators will now be able to produce healthcare advances through Vertu Medical's seamless, programmatic process faster, easier, and with better compensation compared to the existing model of random innovations.

Ultimately, humanity benefits from Vertu Medical by gaining improved technologies that significantly facilitate the human and mechanical diagnostic and interventional arts of medicine. Through the integration of Vertu Medical's revolutionary technological advancements, a broader scope and access to healthcare will be provided, healthcare costs will be reduced, pain and pathology will be better alleviated, leading to enhanced life and longevity for all.

Vertu Innovation Platform

Uniting a Global Community of Innovators

Vertu Medical Technologies

Inventing the Future of Healthcare Technology

Reasons to Invest




Rapid Innovation
Networking


Collaborative Product Development
IDEA
SOLUTION
SUCCESS
NETWORK
INVESTMENT
DECISION
STRATEGY
CONNECTION
ADVICE
NEGOTIATION
BUSINESS
MARKETING
PARTNERSHIP
ORGANIZATION
PLANNING
MARKET
HELPING
TEAMWORK


Artificial
Intelligence


Proprietary Patenting
Process


Medical Technology
Investing



It is said that serendipity is just one percent of life and the other 99 percent stems from the efforts we put forth. Alternatively, for those of us that endeavor to innovate there'll always be serendipity involved in discovery. Innovation is serendipity and therefore one may very well counter argue that serendipity is the destiny of innovators. Nevertheless, your efforts, by chance or not, have granted you permission to board our train so destined toward our mission. A path reserved for the virtuous willing to put forth effort with perseverance and good heart. A path for the faithful and a path for those of us that challenge ourselves to live our lives passionately for the good of all.

Dennis J. Morris, M.D.